Stopping GLP-1 Receptor Agonists Linked to Higher Cardiovascular Risk in Type 2 Diabetes: BMJ Study

What Happens When Patients Stop Taking GLP-1 Receptor Agonists?

GLP-1 receptor agonists — a drug class that includes semaglutide (Ozempic, Wegovy), liraglutide (Victoza), and dulaglutide (Trulicity) — have become cornerstone treatments for type 2 diabetes. Beyond their glucose-lowering effects, landmark trials such as LEADER (liraglutide) and SUSTAIN-6 (semaglutide) have demonstrated significant cardiovascular benefits, leading major guidelines to recommend these agents for patients with established cardiovascular disease or high cardiovascular risk.

The new research published in BMJ Medicine used a target trial emulation framework — an observational study design that mimics randomized trial conditions using real-world data — to investigate what happens when patients discontinue GLP-1 receptor agonist therapy. The findings indicate that stopping treatment may erode the cardiovascular protection these drugs provide, resulting in a higher incidence of major adverse cardiovascular events (MACE), which typically includes heart attack, stroke, and cardiovascular death.

This study is particularly timely given that medication discontinuation is common in real-world practice. Research has consistently shown that adherence to GLP-1 receptor agonists drops significantly over time, with some estimates suggesting that roughly half of patients discontinue within the first year, often due to side effects, cost, or supply issues.

Why Is GLP-1 Agonist Adherence So Important for Heart Health?

GLP-1 receptor agonists exert cardiovascular benefits through several pathways. They reduce inflammation, improve endothelial function, lower blood pressure, promote weight loss, and improve lipid profiles — effects that collectively reduce atherosclerotic cardiovascular disease risk. The American Diabetes Association and European Association for the Study of Diabetes guidelines recommend GLP-1 receptor agonists with proven cardiovascular benefit as preferred agents for patients with type 2 diabetes and atherosclerotic cardiovascular disease.

When patients discontinue these medications, the reversal of these protective mechanisms may leave them vulnerable. Weight regain after stopping GLP-1 agonists is well documented, and the associated metabolic deterioration — including worsening glycemic control, increased blood pressure, and adverse lipid changes — could contribute to elevated cardiovascular risk. The BMJ Medicine findings underscore the importance of strategies to support long-term adherence, including addressing cost barriers, managing side effects proactively, and ensuring continuity of supply.

What Should Patients and Clinicians Take Away From This Research?

The study reinforces an emerging clinical message: GLP-1 receptor agonists are not short-term treatments. For patients with type 2 diabetes and cardiovascular risk factors, these medications may need to be continued long-term to sustain their protective benefits. The International Diabetes Federation estimates that cardiovascular disease accounts for approximately half of all deaths in people with type 2 diabetes, making sustained cardiovascular protection a critical treatment goal.

Clinicians should engage patients in shared decision-making about the importance of treatment persistence, particularly as newer, more potent formulations and oral alternatives become available. For patients who must discontinue due to side effects or other reasons, close cardiovascular monitoring and optimization of other risk factors — including blood pressure, lipids, and glycemic control through alternative agents — becomes especially important. The target trial emulation methodology used in this study adds methodological rigor to observational evidence, though randomized controlled trials examining planned discontinuation strategies would further clarify optimal practice.